🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareBody dysmorphia after significant weight loss — when the mirror lies Page 2

Body dysmorphia after significant weight loss — when the mirror lies

SaraMom3 Mon, Apr 13, 2026 at 5:33 AM 31 replies 1,275 viewsPage 2 of 7
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Apr 13, 2026 at 2:25 PM#6
DataDave said:
Relative and absolute effects need reading together.

I read this differently from DataDave, on substance rather than tone. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

44 14JenMemphis, pat_auckland, Dr.GastroMayo and 41 others
Reply Quote Save Share Report
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Apr 13, 2026 at 5:54 PM#7
SaraMom3 said:
My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my…

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 12,000 GLP-1 users vs matched controls showed reduced stroke risk (HR 0.82) over 3 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
43 13Dr.ObesityLA, NurseKim_ATL, paul_denver and 40 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Apr 13, 2026 at 9:23 PM#8
LabKate said:
I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them.
LabKate said:
...regarding the trial evidence...

I think this is an underappreciated point. To expand on it with some data:

A recent meta-analysis of 18 RCTs (n=15,600) found that the trial evidence was associated with a robust effect size across diverse patient populations[1].

The NNT was 15, which is comparable to statins for secondary prevention. That's a strong clinical argument for this approach.

Last edited: Apr 14, 2026 at 3:23 AM
42 12SurmountFan_IN, PeptideChemSF, A1cHero_PHX and 39 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
mia_MS2
New Member
8
23
Jun 2026
Ann Arbor, MI
Apr 14, 2026 at 12:52 AM#9

One thing that is still open after mike.trainer_LA’s answer:

What would you measure differently if you were starting again?

Last edited: Apr 14, 2026 at 3:52 AM
41 11steve_okc, dave_SLC, FDA_TrackerJim and 38 others
Reply Quote Save Share Report
SaraMom3
Member
456
2,345
Aug 2024
Ohio
Apr 14, 2026 at 5:38 PM#10

Closing the loop on my own question.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.

7 5ZaraB_AL, JakeSmashed95, NauseaFreeNow and 4 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register